Searchable abstracts of presentations at key conferences in endocrinology

ea0081p220 | Thyroid | ECE2022

Alpelisib-induced thyroiditis in a patient with metastatic breast carcinoma

Prem Kumar Anusha , Flynn Calvin , J Higgins Michaela , K Crowley Rachel , O'Shea Donal , Garrahy Aoife

Background: Alpelisib is a novel phosphotidylinositol 3-kinase (PI3K) inhibitor which, in combination with fulvestrant, has been shown to increase progression-free survival in patients with HR+/HER2-/PI3KCA mutated advanced breast cancer[1]. Hyperglycaemia, including alpelisib-induced diabetic ketoacidosis is a known adverse effect, along with rash, diarrhoea and stomatitis. No other associated endocrinopathy has been reported to date. Case presentation: We present th...

ea0070aep130 | Bone and Calcium | ECE2020

Phase II study of the impact of AZD4017, a selective 11β-HSD1 inhibitor, on osteocalcin in post-menopausal osteopenia

Abbas Afroze , Eastell Richard , K Crowley Rachel , Ainsworth Gemma , Brown Sarah , Flanagan Louise M , Fairclough Rebecca J , Stewart Paul M

The causative link between circulating glucocorticoid excess and osteoporosis is established. Although circulating cortisol levels do not change significantly with age, local tissue metabolism may be implicated in age-related bone loss. The enzyme11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) increases local cortisol production, is expressed in human osteoblasts and its activity increases with age leading to a decrease in bone formation. We hypothesised that sele...